Coherus Biosciences (CHRS) EBITDA (2013 - 2026)
Coherus Biosciences (CHRS) EBITDA from Sep 30, 2013 to Mar 31, 2026. The TTM Coherus Biosciences (CHRS) EBITDA is -$170M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
Coherus Biosciences (CHRS) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | -3.31% |
| 3 Years TTM | -10.84% |
| 5 Years TTM | +28.38% |
| 10 Years TTM | -3.56% |
| All Time TTM | +14.00% |
Annual EBITDA change of Coherus Biosciences (CHRS)
| Year | EBITDA | Change |
|---|---|---|
| 2026 | -$35M | -80.39% |
| 2025 | -$180M | -9.20% |
| 2024 | -$198M | -0.97% |
| 2023 | -$200M | -21.04% |
| 2022 | -$253M | -2.72% |
| 2021 | -$260M | -263.53% |
| 2020 | $159M | +43.39% |
| 2019 | $111M | -155.19% |
| 2018 | -$201M | -12.05% |
| 2017 | -$229M | +102.55% |
| 2016 | -$113M | -48.01% |
| 2015 | -$217M | +239.32% |
| 2014 | -$64M | +79.85% |
| 2013 | -$36M | -7.08% |
| 2012 | -$38M | N/A |
Comparison Coherus Biosciences (CHRS) five years EBITDA CAGR with competitors
Coherus Biosciences (CHRS) five years EBITDA CAGR is 28.37%.